دورية أكاديمية

Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor.

التفاصيل البيبلوغرافية
العنوان: Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor.
المؤلفون: Grosenbaugh DA; Merial Limited, 1730 Olympic Dr, Athens, GA 30601, USA. Deborah.Grosenbaugh@merial.com, Leard AT, Bergman PJ, Klein MK, Meleo K, Susaneck S, Hess PR, Jankowski MK, Jones PD, Leibman NF, Johnson MH, Kurzman ID, Wolchok JD
المصدر: American journal of veterinary research [Am J Vet Res] 2011 Dec; Vol. 72 (12), pp. 1631-8.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: American Veterinary Medical Association Country of Publication: United States NLM ID: 0375011 Publication Model: Print Cited Medium: Internet ISSN: 1943-5681 (Electronic) Linking ISSN: 00029645 NLM ISO Abbreviation: Am J Vet Res Subsets: MEDLINE
أسماء مطبوعة: Publication: Schaumburg, Ill. : American Veterinary Medical Association
Original Publication: Chicago : American Veterinary Medical Assn.
مواضيع طبية MeSH: Cancer Vaccines/*therapeutic use , Dog Diseases/*drug therapy , Melanoma/*veterinary , Monophenol Monooxygenase/*therapeutic use , Mouth Neoplasms/*veterinary , Vaccines, DNA/*therapeutic use, Administration, Cutaneous ; Animals ; Cancer Vaccines/immunology ; DNA, Complementary/genetics ; DNA, Complementary/therapeutic use ; Dog Diseases/immunology ; Dogs ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Male ; Melanoma/drug therapy ; Melanoma/immunology ; Monophenol Monooxygenase/genetics ; Mouth Neoplasms/drug therapy ; Mouth Neoplasms/immunology ; Neoplasm Staging/veterinary ; Oral Surgical Procedures/veterinary ; Plasmids/genetics ; Plasmids/therapeutic use ; Prospective Studies ; Treatment Outcome ; United States ; Vaccines, DNA/immunology
مستخلص: Objective: To evaluate the safety and efficacy of a vaccine containing plasmid DNA with an insert encoding human tyrosinase (ie, huTyr vaccine) as adjunctive treatment for oral malignant melanoma (MM) in dogs.
Animals: 111 dogs (58 prospectively enrolled in a multicenter clinical trial and 53 historical controls) with stage II or III oral MM (modified World Health Organization staging scale, I to IV) in which locoregional disease control was achieved.
Procedures: 58 dogs received an initial series of 4 injections of huTyr vaccine (102 μg of DNA/injection) administered transdermally by use of a needle-free IM vaccination device. Dogs were monitored for adverse reactions. Surviving dogs received booster injections at 6-month intervals thereafter. Survival time for vaccinates was compared with that of historical control dogs via Kaplan-Meier survival analysis for the outcome of death.
Results: Kaplan-Meier analysis of survival time until death attributable to MM was determined to be significantly improved for dogs that received the huTyr vaccine, compared with that of historical controls. However, median survival time could not be determined for vaccinates because < 50% died of MM before the end of the observation period. No systemic reactions requiring veterinary intervention were associated with vaccination. Local reactions were primarily limited to acute wheal or hematoma formation, mild signs of pain at the injection site, and postvaccination bruising.
Conclusions and Clinical Relevance: Results support the safety and efficacy of the huTyr DNA vaccine in dogs as adjunctive treatment for oral MM.
Impact for Human Medicine: Response to DNA vaccination in dogs with oral MM may be useful in development of plasmid DNA vaccination protocols for human patients with similar disease.
معلومات مُعتمدة: P30 CA008748 United States CA NCI NIH HHS; P01 CA33049 United States CA NCI NIH HHS
المشرفين على المادة: 0 (Cancer Vaccines)
0 (DNA, Complementary)
0 (Vaccines, DNA)
EC 1.14.18.1 (Monophenol Monooxygenase)
تواريخ الأحداث: Date Created: 20111201 Date Completed: 20120321 Latest Revision: 20211021
رمز التحديث: 20240829
DOI: 10.2460/ajvr.72.12.1631
PMID: 22126691
قاعدة البيانات: MEDLINE
الوصف
تدمد:1943-5681
DOI:10.2460/ajvr.72.12.1631